Campbell & Co Investment Adviser’s Cytokinetics CYTK Stock Holding History

Campbell & Co Investment Adviser’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.62M	Buy	+65,978	New	+$4.74M	0.29%	56
2026 Q1	–	Sell	-96,484	Closed	-$6.13M	–	1144
2025 Q4	$6.13M	Buy	+96,484	New	+$6M	0.29%	64
2024 Q3	–	Sell	-12,506	Closed	-$678K	–	1139
2024 Q2	$678K	Buy	+12,506	New	+$755K	0.06%	529
2023 Q4	–	Sell	-28,159	Closed	-$830K	–	1144
2023 Q3	$830K	Buy	28,159 +14,180	+101%	+$472K	0.1%	332
2023 Q2	$456K	Buy	+13,979	New	+$517K	0.08%	481
2022 Q3	–	Sell	-20,328	Closed	-$799K	–	748
2022 Q2	$799K	Buy	+20,328	New	+$818K	0.22%	131
2019 Q2	–	Sell	-43,844	Closed	-$355K	–	563
2019 Q1	$355K	Buy	+43,844	New	+$322K	0.17%	221
2017 Q1	–	Sell	-10,500	Closed	-$128K	–	163
2016 Q4	$128K	Buy	+10,500	New	+$111K	0.4%	112

Other funds holding CYTK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Campbell & Co Investment Adviser's CYTK Position: Q2 2026 in Review

Campbell & Co Investment Adviser opened a new position in Cytokinetics (CYTK) in Q2 2026: 65,978 shares worth $5.62M. The stake represents 0.29% of the portfolio and ranks #56 among its holdings. This is a return to the name: Campbell & Co Investment Adviser previously reported a position in CYTK as recently as Q4 2025.

Campbell & Co Investment Adviser first reported a position in CYTK in Q4 2016 and has held it in 8 quarters since. The position peaked at $6.13M in Q4 2025. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

Campbell & Co Investment Adviser held 65,978 shares of Cytokinetics worth $5.62M as of Q2 2026.
Cytokinetics was a new Campbell & Co Investment Adviser position in Q2 2026.
Cytokinetics made up 0.29% of Campbell & Co Investment Adviser's portfolio in Q2 2026, its #56 holding.
Campbell & Co Investment Adviser first reported a position in Cytokinetics in Q4 2016 and has held it in 8 quarters since.
Campbell & Co Investment Adviser's Cytokinetics position peaked at $6.13M in Q4 2025.
482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Campbell & Co Investment Adviser's 13F filing for Q2 2026, filed 3 Aug 2026.